Drug Profile
TTP 435
Alternative Names: TTP435Latest Information Update: 18 Aug 2015
Price :
$50
*
At a glance
- Originator TransTech Pharma
- Developer vTv Therapeutics
- Class Anorectics; Small molecules
- Mechanism of Action Agouti-related protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 18 Aug 2015 Discontinued - Phase-II for Obesity in USA and Canada (PO)
- 31 Jul 2007 Phase-I clinical trials in Obesity in USA (unspecified route)